Global pharma major Lupin Limited (Lupin) has announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, to market a generic equivalent of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, of Janssen Research and Development, LLC.

Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).